Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
NBI-1117568 by Neurocrine Biosciences for Schizophrenia: Likelihood of Approval
NBI-1117568 is under clinical development by Neurocrine Biosciences and currently in Phase II for Schizophrenia. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of Neurocrine Biosciences's NBI-1117568?
NBI-1117568 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase II program in Schizophrenia. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Neurocrine Biosciences's NBI-1117568?
NBI-1117568 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase II program in Schizophrenia. According to Globaldata,...